Cargando…
Identification of novel anti-tumor therapeutic target via proteomic characterization of ubiquitin receptor ADRM1/Rpn13
Autores principales: | Song, Yan, Du, Ting, Ray, Arghya, Chauhan, Krishan, Samur, Mehmet, Munshi, Nikhil, Chauhan, Dharminder, Anderson, Kenneth C. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7806750/ https://www.ncbi.nlm.nih.gov/pubmed/33441535 http://dx.doi.org/10.1038/s41408-020-00398-9 |
Ejemplares similares
-
Blockade of ubiquitin receptor Rpn13 in plasmacytoid dendritic cells triggers anti-myeloma immunity
por: Ray, Arghya, et al.
Publicado: (2019) -
Chirality and asymmetry increase the potency of candidate ADRM1/RPN13 inhibitors
por: Anchoori, Ravi K., et al.
Publicado: (2021) -
RPN13/ADRM1 inhibitor reverses immunosuppression by myeloid-derived suppressor cells
por: Soong, Ruey-Shyang, et al.
Publicado: (2016) -
Analysis of COVID-19-Associated Proteins Identifies TANK-Binding Kinase 1 As an Immunotherapeutic Target in Multiple Myeloma
por: Ray, Arghya, et al.
Publicado: (2022) -
Development and anticancer properties of Up284, a spirocyclic candidate ADRM1/RPN13 inhibitor
por: Anchoori, Ravi K., et al.
Publicado: (2023)